Project Grant R01CA315392
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $657K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- The National Cancer Institute, within the Department of Health and Human Services, awarded Dana-Farber Cancer Institute, Inc. $718,275 on July 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate context-specific pathway dependencies for nuclear envelope proteins in brain cancer. The research addresses how nuclear envelope-associated proteins perform distinct biochemical functions across different cellular contexts in central nervous system cancers. The project uses an...
- The National Cancer Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded Dana-Farber Cancer Institute, Inc. $134,919 under the Cancer Research Manpower program (CFDA 93.398) on June 11, 2026. The award funds structure-function and mechanistic studies of the protein-O-mannosyl transferase (POMT) complex in pediatric low-grade gliomas driven by the KIAA1549:BRAF fusion. The research aims to determine high-resolution structures of the POMT...
- The National Cancer Institute awarded New York University $110,228 on January 15, 2027, under the Cancer Research Manpower program (CFDA 93.398) to develop isoform-selective synthetic binding proteins against RAF kinases as a strategy for precise disruption of RAF-mediated signaling in cancers. The project targets protein-protein interactions central to the RAS-RAF pathway, a key cancer driver. Current FDA-approved RAF kinase inhibitors lack isoform specificity and paradoxically activate...
- The National Cancer Institute awarded Dana-Farber Cancer Institute $643,414 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop an interleukin-21 mimic compound, designated 21H10, that enhances anti-tumor immunity in pancreatic ductal adenocarcinoma. The research centers on combining 21H10 with KRAS inhibitors to convert transient therapeutic responses into durable remissions in pancreatic cancer. The compound was developed using AI-assisted computational...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc., $144,035 on September 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research dissecting transcription factor-mediated chromatin remodeling complex activities in human cancer. The funded work integrates biochemistry, structural biology, functional genomics, and chemical biology approaches to define how BAF (mammalian SWI/SNF) chromatin remodeling complexes are recruited by transcription...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $606,749 on August 13, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate novel functions of cell cycle proteins in G1/S phase progression and cancer. The research examines the molecular roles of the cyclin B–CDK1 kinase complex in regulating cell cycle entry and DNA synthesis. Aim 1 uses mouse and human cells to identify the range of molecular functions played by cyclin B–CDK1 during G1/S phase....
- The National Cancer Institute awarded Duke University $693,403 in Cancer Treatment Research funding on June 9, 2026, to identify and inhibit novel downstream effectors of mutant RAS in RAS-driven cancers. The research addresses the limited treatment options for cancers carrying activating RAS mutations. KRAS is the most commonly mutated oncogene in human cancers, but existing inhibitors such as AM510 target only KRASG12C, which occurs in approximately 13 percent of lung adenocarcinoma, 3 percent...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $645,102 on July 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to support research investigating the molecular mechanisms governing WEE1 kinase transition from CDK inhibitor to substrate in cell cycle control. The project addresses how WEE1 kinase shifts between functioning as an active enzyme and as a substrate for phosphorylation at the G2-to-M cell cycle checkpoint. The work focuses on the N-terminal...
- The National Cancer Institute awarded The University of Texas Southwestern Medical Center $131,727 on May 7, 2026, under the Cancer Research Manpower program (CFDA 93.398) to characterize a novel covalent RAS dimer in RASQ61 mutants and develop therapeutic strategies targeting those mutations commonly found in melanoma, leukemia, thyroid cancer, and lung cancer. The award funds investigator-initiated basic biomedical research focused on understanding RAS protein-protein interactions and...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $528,099 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to characterize therapeutic vulnerabilities in ovarian clear cell carcinoma and develop new treatment strategies for both ARID1A-mutant and ARID1A-wildtype disease. The funded research identifies the PI3K/mTOR and HIF/VEGF pathways as fundamental therapeutic targets in ovarian clear cell carcinoma, with particular focus on synergy...